Cargando…

Phase I study of 21 days continuous infusion with vindesine.

Detalles Bibliográficos
Autores principales:	de Vries, E. G., Smit, E. F., Vendrig, D. E., Holthuis, J. J., Mulder, N. H.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1989
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247064/ https://www.ncbi.nlm.nih.gov/pubmed/2930717

Ejemplares similares

Cytotoxicity of etretinate and vindesine.
por: Gaukroger, J. M., et al.
Publicado: (1985)

Biochemical effects of vindesine.
por: Creasey, W. A.
Publicado: (1981)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine.
por: Evans, B. D., et al.
Publicado: (1982)

A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
por: Nakano, T., et al.
Publicado: (1996)

A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro.
por: Johnson, J. R., et al.
Publicado: (1981)

Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.
por: Groen, H. J., et al.
Publicado: (1995)

Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.
por: Embleton, M. J., et al.
Publicado: (1983)

Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.
por: Ford, C. H., et al.
Publicado: (1983)

Vindesine receptors in cells of a human leukaemia cell line.
por: Totsuka, K., et al.
Publicado: (1982)

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer
por: Sørensen, J B, et al.
Publicado: (1999)

A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
por: Ando, M., et al.
Publicado: (1998)

Characterisation of a vindesine-resistant human small-cell lung cancer cell line.
por: Ohta, S., et al.
Publicado: (1993)

Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
por: Foster, B. J., et al.
Publicado: (1993)

Enhancement of cytotoxicity of vindesine and cis-platinum for human lung tumours by the use of verapamil in vitro.
por: Simmonds, A. P., et al.
Publicado: (1986)

Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer
por: Park, Se Hoon, et al.
Publicado: (2005)

Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine
por: Dhyani, Praveen, et al.
Publicado: (2022)

Prolonged continuous infusion of low-dose rIL-2.
por: Janssen, R. A., et al.
Publicado: (1994)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.
por: Woods, R. L., et al.
Publicado: (1990)

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
por: Gietema, J. A., et al.
Publicado: (1993)

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
por: Vlasveld, L. T., et al.
Publicado: (1992)

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
por: Awada, A, et al.
Publicado: (2005)

Continuous IV infusion of anakinra
por: Saunders, Brittney N., et al.
Publicado: (2023)

Infusing 21st Century Skill Development into the Undergraduate Curriculum: The Formation of the iBEARS Network
por: St. Louis, Alex T., et al.
Publicado: (2021)

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days
por: Bilenker, J H, et al.
Publicado: (2004)

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2004)

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.
por: Vlasveld, L. T., et al.
Publicado: (1993)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
por: Furuse, K., et al.
Publicado: (1997)

Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study
por: Konings, Inge R. H. M., et al.
Publicado: (2010)

Continuous Intravenous Infusion
por: Farquharson, Eric L.
Publicado: (1934)

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
por: Paz-Ares, L., et al.
Publicado: (1998)

A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma
por: Crawley, Charles R., et al.
Publicado: (1997)

A Two-Day Continuous Nicotine Infusion Is Sufficient to Demonstrate Nicotine Withdrawal in Rats as Measured Using Intracranial Self-Stimulation
por: Muelken, Peter, et al.
Publicado: (2015)

A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
por: Evans, T. R., et al.
Publicado: (1996)

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
por: Zhai, Yujia, et al.
Publicado: (2021)

Acute and Persistent Remission of Aggressive Natural Killer Cell Leukemia in an Older Patient Induced by Chidamide Combined with Cyclophosphamide, Vindesine, Prednisone, and Etoposide Therapy
por: Lin, Qingqing, et al.
Publicado: (2023)

Metabolism of ifosfamide during a 3 day infusion.
por: Hartley, J. M., et al.
Publicado: (1994)

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
por: Benson, C, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_6i395ss6m5nklv67hiji8grb8r